King Pharmaceuticals, Inc. (NYSE:KG)

CAPS Rating: 3 out of 5

The Company is a vertically integrated pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products.

Results 1 - 20 of 44 : 1 2 3 Next »

Recs

0
Member Avatar btthus (22.14) Submitted: 10/12/2010 11:10:01 AM : Outperform Start Price: $14.16 KG Score: -64.91

Price is now 14.15....
Pfizer will acquire King Pharma for $14.25 per share.

Recs

0
Member Avatar coryjobe (93.37) Submitted: 7/24/2010 3:58:39 PM : Outperform Start Price: $8.51 KG Score: -12.67

Recently had a slight setback with their drug Acurox, FDA rejected it but there is still a chance that it will get passed if the regulator says its ok. Right now they plan on submitting a new application in early 2011 with a new version of the drug that will have much better odds of getting approved. This company might not have much growth short term, but in the long term should be very profitable. They have a large number of drugs which should boost numbers in the next couple of years. Also a court ruling is causing one of the generic competitors Skelaxin off the market for now.

Recs

0
Member Avatar OpesPerPrudentia (90.28) Submitted: 4/2/2010 1:57:04 AM : Outperform Start Price: $11.96 KG Score: -43.89

Hypothyroidism based weightloss craze mixed with universal mandated healthcare = big bucks for companies that manufacture thyroid hormone drugs.

Recs

0
Member Avatar fooljh123457 (< 20) Submitted: 8/17/2009 5:37:15 PM : Outperform Start Price: $10.43 KG Score: -59.97

new technology they have fixed it to prevent abuse of over doing for affect. docs will be more likely to prefer this med over others that can be abused for recreation purposes. docs will flock to this med!

Recs

0
Member Avatar spotpetes (< 20) Submitted: 8/13/2009 3:18:11 PM : Outperform Start Price: $10.57 KG Score: -56.76

Good looking company....

Recs

0
Member Avatar tone17 (33.75) Submitted: 5/20/2009 8:17:28 PM : Outperform Start Price: $8.96 KG Score: -58.71

New meds

Recs

0
Member Avatar JMartinBlack (47.15) Submitted: 4/17/2009 4:15:13 PM : Outperform Start Price: $8.84 KG Score: -66.52

King pharm has been performing well for me over the past month

Recs

0
Member Avatar adavisclan (78.72) Submitted: 2/18/2009 11:16:08 AM : Outperform Start Price: $8.35 KG Score: -76.71

At 0.3, low debt to equity reducing risk in these tight money times. Forward P/E of 6.9x versus industry P/E of 10.8x. Price to sales of 1.0x versus industry of 2.4x. These numbers would seem to make KG an attractive take over target to a larger Pharma.

While two of King's Skelaxin patents have been invalidated and may result in a generic release, thier integration of AlphaPharma should more than offset any loss market in Skelaxin while also offering some synergistic cost savings.

Recs

0
Member Avatar YoungNGunnin (< 20) Submitted: 1/14/2009 11:54:13 AM : Outperform Start Price: $9.16 KG Score: -76.93

Been heading south bound to head back up

Recs

1
Member Avatar Survivn2 (28.66) Submitted: 10/16/2008 2:00:02 AM : Outperform Start Price: $7.99 KG Score: -37.73

Pharma in rough times, MFI. Smaller cap than I wanted, but we'll give it a try.

Recs

1
Member Avatar RxIntern (< 20) Submitted: 9/6/2008 1:31:14 AM : Outperform Start Price: $11.99 KG Score: -36.47

New Pain Meds = high profits!

Recs

1
Member Avatar oxsigtech (27.55) Submitted: 8/12/2008 9:50:44 AM : Outperform Start Price: $11.27 KG Score: -26.49

They have had some rough times in the past, but these guys sell a lot of generic drugs.

Recs

0
Member Avatar Dragontoad2 (86.02) Submitted: 7/2/2008 9:14:19 AM : Outperform Start Price: $10.50 KG Score: -18.59

price/book =1.. solid numbers

Recs

0
Member Avatar NASAGeek (89.72) Submitted: 6/26/2008 9:21:56 PM : Outperform Start Price: $9.91 KG Score: -11.15

magicformulainvesting.com screen at $153M market cap, top 25 companies on June 26, 2008

Recs

0
Member Avatar twistright (< 20) Submitted: 6/11/2008 7:38:25 PM : Outperform Start Price: $9.40 KG Score: +3.25

increase in businesses offering fixed price prescriptions will boost near term demand for generics.

Recs

1
Member Avatar angus118 (20.08) Submitted: 5/22/2008 11:48:13 AM : Outperform Start Price: $9.85 KG Score: +1.24

King Pharmaceuticals KG has been hurt by the loss of a patent dispute last year for the key ingredient in its hypertension drug Altace. The result has been generic competition for the drug much sooner than anticipated and this is having a negative effect on revenues and margins. As a result King has laid off 20% of its work and refocused its efforts on the neuroscience, hospital and acute care markets. The neuroscience division in particular could be very attractive should they receive FDA approval for their abuse resistant pain drug Remoxy. They hope to have the drug to market by 2009 and it is a potential blockbuster. The stock trades just off its 52-week lows and has a bulletproof balance sheet with over 60% of the stock price in cash. The EV/EBITDA ratio is just 1.5 and equally attractive to the asset-loving side of me, it trading at 85% of book value. It is worth a look at these levels. Tim Melvin - thestreet.com

Recs

0
Member Avatar noparking (< 20) Submitted: 5/14/2008 10:40:59 AM : Outperform Start Price: $9.70 KG Score: +5.83

The King of... something.

Recs

0
Member Avatar dothedow (25.11) Submitted: 5/3/2008 12:41:16 AM : Outperform Start Price: $9.62 KG Score: +6.35

valuepick

Recs

0
Member Avatar tnlbohrer (41.80) Submitted: 5/2/2008 10:45:04 AM : Outperform Start Price: $9.74 KG Score: +4.94

Buying low. Good Company with a wide variety of products.

Recs

0
Member Avatar paultaut (< 20) Submitted: 4/25/2008 4:58:42 PM : Outperform Start Price: $9.11 KG Score: +13.39

why not

Results 1 - 20 of 44 : 1 2 3 Next »

Featured Broker Partners


Advertisement